Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia
June 22, 2017 08:30 ET
|
Minerva Neurosciences, Inc.
New formulation observed to improve safety margin while offering bioequivalent exposure to prior formulation Company to proceed with initiation of Phase 3 trial on schedule in second half of 2017 ...
Minerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia
October 26, 2016 08:30 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...